Symbols / CMPX Stock $1.87 +2.19% Compass Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
CMPX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Thomas J. Schuetz M.D., Ph.D.
Exch · Country NCM · United States
Market Cap 336.76M
Enterprise Value 151.87M
Income -68.17M
Sales —
FCF (ttm) -30.04M
Book/sh 1.10
Cash/sh 1.08
Employees 39
Insider 10d —
IPO Apr 05, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -4.36
PEG —
P/S —
P/B 1.69
P/C —
EV/EBITDA -2.02
EV/Sales —
Quick Ratio 18.94
Current Ratio 19.04
Debt/Eq 5.25
LT Debt/Eq —
EPS (ttm) -0.40
EPS next Y -0.43
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-05
Earnings (prior) 2026-05-05
ROA -27.91%
ROE -45.95%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 180.09M
Shs Float 122.29M
Insider Own 12.46%
Instit Own 90.46%
Short Float 20.19%
Short Ratio 2.39
Short Interest 30.42M
52W High 6.88
vs 52W High -72.82%
52W Low 1.61
vs 52W Low 16.15%
Beta 0.67
Impl. Vol. 12.50%
Rel Volume 0.74
Avg Volume 7.03M
Volume 5.17M
Target (mean) $10.58
Tgt Median $7.50
Tgt Low $4.00
Tgt High $30.00
# Analysts 12
Recom Strong_buy
Prev Close $1.83
Price $1.87
Change 2.19%
About

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$10.58
Mean price target
2. Current target
$1.87
Latest analyst target
3. DCF / Fair value
$-3.00
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.87
Low
$4.00
High
$30.00
Mean
$10.58

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-28 main Canaccord Genuity Buy → Buy $7
2026-04-28 reit Citizens Market Outperform → Market Outperform $10
2026-04-27 reit HC Wainwright & Co. Buy → Buy $24
2026-04-27 main D. Boral Capital Buy → Buy $30
2026-03-24 reit Guggenheim Buy → Buy $12
2026-01-06 main D. Boral Capital Buy → Buy $30
2026-01-05 init William Blair — → Outperform —
2025-12-03 init Cantor Fitzgerald — → Overweight —
2025-12-03 init Citizens — → Market Outperform $10
2025-12-03 init Canaccord Genuity — → Buy $10
2025-11-05 main D. Boral Capital Buy → Buy $30
2025-10-06 init LifeSci Capital — → Outperform $10
2025-08-12 main D. Boral Capital Buy → Buy $32
2025-08-12 main Guggenheim Buy → Buy $12
2025-05-09 main Guggenheim Buy → Buy $10
2025-04-28 main D. Boral Capital Buy → Buy $32
2025-04-22 reit Guggenheim Buy → Buy —
2025-04-21 reit HC Wainwright & Co. Buy → Buy $24
2025-04-21 main D. Boral Capital Buy → Buy $32
2025-04-04 main HC Wainwright & Co. Buy → Buy $24
News
RSS: Latest CMPX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-29 LERNER NEIL L Officer — 15,000 $1.89 $28,350
2026-04-29 ANDERMAN JONATHAN General Counsel — 25,000 $1.89 $47,250
2026-04-29 LERNER NEIL L Officer — 15,000 $1.89 $28,350
2026-04-29 ANDERMAN JONATHAN General Counsel — 25,000 $1.89 $47,250
2026-01-02 LERNER NEIL L Officer — 62,500 $5.17 $323,125
2026-01-02 SCHUETZ THOMAS J. Chief Executive Officer — 250,000 $5.17 $1,292,500
2026-01-02 SHIN BARRY Chief Financial Officer — 125,000 $5.17 $646,250
2026-01-02 ANDERMAN JONATHAN General Counsel — 150,000 $5.17 $775,500
2025-05-27 SCHUETZ THOMAS J. Chief Executive Officer — 10,000 $2.11 $21,100
2025-04-07 LERNER NEIL L Officer — 20,000 $1.42 $28,400
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
-100.00%
0.85
0.00
0.00
Operating Revenue
0.00
-100.00%
0.85
0.00
0.00
Operating Expense
72.84
+26.73%
57.48
+14.12%
50.36
+20.91%
41.66
Research And Development
55.97
+32.18%
42.34
+11.08%
38.12
+27.08%
30.00
Selling General And Administration
16.87
+11.48%
15.13
+23.61%
12.24
+5.02%
11.66
General And Administrative Expense
16.87
+11.48%
15.13
+23.61%
12.24
+5.02%
11.66
Other Gand A
16.87
+11.48%
15.13
+23.61%
12.24
+5.02%
11.66
Total Expenses
72.84
+26.73%
57.48
+14.12%
50.36
+20.91%
41.66
Operating Income
-72.84
-28.63%
-56.62
-12.43%
-50.36
-20.91%
-41.66
Total Operating Income As Reported
-72.84
-28.63%
-56.62
-12.43%
-50.36
-20.91%
-41.66
EBITDA
-71.37
-30.06%
-54.87
-13.20%
-48.47
-21.94%
-39.75
Normalized EBITDA
-71.37
-30.06%
-54.87
-13.20%
-48.47
-21.73%
-39.82
Reconciled Depreciation
1.47
-16.03%
1.75
-7.25%
1.89
-0.74%
1.90
EBIT
-72.84
-28.63%
-56.62
-12.43%
-50.36
-20.91%
-41.66
Total Unusual Items
—
—
0.00
-100.00%
0.07
Total Unusual Items Excluding Goodwill
—
—
0.00
-100.00%
0.07
Special Income Charges
—
—
0.00
-100.00%
0.07
Other Special Charges
—
—
—
—
Net Income
-66.49
-34.66%
-49.38
-16.19%
-42.49
-8.33%
-39.23
Pretax Income
-66.49
-34.66%
-49.38
-16.19%
-42.49
-8.33%
-39.23
Net Non Operating Interest Income Expense
6.40
-12.33%
7.30
-7.59%
7.90
+234.75%
2.36
Interest Expense Non Operating
—
—
—
0.00
Net Interest Income
6.40
-12.33%
7.30
-7.59%
7.90
+234.75%
2.36
Interest Expense
—
—
—
0.00
Interest Income Non Operating
6.40
-12.33%
7.30
-7.59%
7.90
+234.75%
2.36
Interest Income
6.40
-12.33%
7.30
-7.59%
7.90
+234.75%
2.36
Other Income Expense
-0.05
+0.00%
-0.05
-61.29%
-0.03
-144.29%
0.07
Other Non Operating Income Expenses
-0.05
+0.00%
-0.05
-61.29%
-0.03
—
Tax Provision
—
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-66.49
-34.66%
-49.38
-16.19%
-42.49
-8.33%
-39.23
Net Income From Continuing Operation Net Minority Interest
-66.49
-34.66%
-49.38
-16.19%
-42.49
-8.33%
-39.23
Net Income From Continuing And Discontinued Operation
-66.49
-34.66%
-49.38
-16.19%
-42.49
-8.33%
-39.23
Net Income Continuous Operations
-66.49
-34.66%
-49.38
-16.19%
-42.49
-8.33%
-39.23
Normalized Income
-66.49
-34.66%
-49.38
-16.19%
-42.49
-8.14%
-39.30
Net Income Common Stockholders
-66.49
-34.66%
-49.38
-16.19%
-42.49
-8.33%
-39.23
Diluted EPS
—
-0.36
-9.09%
-0.33
+10.81%
-0.37
Basic EPS
—
-0.36
-9.09%
-0.33
+10.81%
-0.37
Basic Average Shares
—
137.15
+7.97%
127.03
+20.76%
105.19
Diluted Average Shares
—
137.15
+7.97%
127.03
+20.76%
105.19
Diluted NI Availto Com Stockholders
-66.49
-34.66%
-49.38
-16.19%
-42.49
-8.33%
-39.23
Gain On Sale Of PPE
—
—
0.00
-100.00%
0.07
Line Item Trend 2021-12-31
Total Assets
—
Current Assets
—
Cash Cash Equivalents And Short Term Investments
—
Cash And Cash Equivalents
—
Other Short Term Investments
—
Prepaid Assets
2.59
Other Current Assets
—
Total Non Current Assets
—
Net PPE
—
Gross PPE
—
Accumulated Depreciation
—
Properties
—
Machinery Furniture Equipment
—
Other Properties
—
Leases
—
Other Non Current Assets
—
Total Liabilities Net Minority Interest
—
Current Liabilities
—
Payables And Accrued Expenses
—
Payables
—
Accounts Payable
—
Current Accrued Expenses
—
Pensionand Other Post Retirement Benefit Plans Current
—
Current Debt And Capital Lease Obligation
—
Current Capital Lease Obligation
—
Total Non Current Liabilities Net Minority Interest
—
Long Term Debt And Capital Lease Obligation
—
Long Term Capital Lease Obligation
—
Other Non Current Liabilities
—
Stockholders Equity
—
Common Stock Equity
—
Capital Stock
—
Common Stock
—
Preferred Stock
0.00
Share Issued
—
Ordinary Shares Number
—
Treasury Shares Number
0.47
Additional Paid In Capital
—
Retained Earnings
—
Gains Losses Not Affecting Retained Earnings
—
Other Equity Adjustments
—
Total Equity Gross Minority Interest
—
Total Capitalization
—
Working Capital
—
Invested Capital
—
Total Debt
—
Capital Lease Obligations
—
Net Tangible Assets
—
Tangible Book Value
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-49.14
-9.56%
-44.85
-10.43%
-40.62
-19.03%
-34.12
Cash Flow From Continuing Operating Activities
-49.14
-9.56%
-44.85
-10.43%
-40.62
-19.03%
-34.12
Net Income From Continuing Operations
-66.49
-34.66%
-49.38
-16.19%
-42.49
-8.33%
-39.23
Depreciation Amortization Depletion
1.47
-16.03%
1.75
-7.25%
1.89
-0.74%
1.90
Depreciation
1.47
-16.03%
1.75
-7.25%
1.89
-0.74%
1.90
Depreciation And Amortization
1.47
-16.03%
1.75
-7.25%
1.89
-0.74%
1.90
Other Non Cash Items
—
—
—
—
Stock Based Compensation
8.37
-2.24%
8.56
+39.87%
6.12
+14.82%
5.33
Asset Impairment Charge
—
—
—
0.00
Operating Gains Losses
—
—
—
-0.07
Gain Loss On Sale Of PPE
—
—
0.00
+100.00%
-0.07
Change In Working Capital
9.18
+321.61%
-4.14
-42.43%
-2.91
-130.25%
-1.26
Change In Prepaid Assets
5.12
+205.33%
-4.86
-171.83%
6.76
+220.94%
-5.59
Change In Payables And Accrued Expense
4.43
+129.40%
1.93
+122.82%
-8.47
-255.95%
5.43
Change In Accrued Expense
5.10
+35.06%
3.77
+141.12%
-9.18
-414.79%
2.92
Change In Payable
-0.66
+63.93%
-1.84
-360.03%
0.71
-71.85%
2.52
Change In Account Payable
-0.66
+63.93%
-1.84
-360.03%
0.71
-71.85%
2.52
Change In Other Current Assets
—
—
—
—
Change In Other Current Liabilities
-0.37
+69.68%
-1.22
-1.25%
-1.20
-9.07%
-1.10
Investing Cash Flow
-93.31
-299.49%
46.77
+73.45%
26.96
+117.83%
-151.20
Cash Flow From Continuing Investing Activities
-93.31
-299.49%
46.77
+73.45%
26.96
+117.83%
-151.20
Net PPE Purchase And Sale
-0.03
+43.18%
-0.04
-46.67%
-0.03
+16.67%
-0.04
Purchase Of PPE
-0.03
+43.18%
-0.04
-46.67%
-0.03
+85.85%
-0.21
Sale Of PPE
—
—
0.00
-100.00%
0.18
Capital Expenditure
-0.03
+43.18%
-0.04
-46.67%
-0.03
+85.85%
-0.21
Net Investment Purchase And Sale
-93.28
-299.25%
46.82
+73.42%
27.00
+117.86%
-151.16
Purchase Of Investment
-194.56
-120.69%
-88.16
+43.28%
-155.42
+22.34%
-200.12
Sale Of Investment
101.28
-24.97%
134.97
-26.01%
182.41
+272.61%
48.95
Net Other Investing Changes
—
—
—
—
Financing Cash Flow
129.61
+647.54%
17.34
+490.73%
2.94
-96.13%
75.76
Cash Flow From Continuing Financing Activities
129.61
+647.54%
17.34
+490.73%
2.94
-96.13%
75.76
Net Issuance Payments Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
—
0.00
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
138.00
+661.88%
18.11
+479.43%
3.13
-95.90%
76.24
Proceeds From Stock Option Exercised
1.27
0.00
-100.00%
0.06
+313.33%
0.01
Net Other Financing Charges
-9.66
-1147.10%
-0.78
-206.32%
-0.25
+48.89%
-0.49
Changes In Cash
-12.84
-166.68%
19.25
+279.65%
-10.72
+90.22%
-109.57
Beginning Cash Position
44.05
+81.82%
24.23
-30.67%
34.95
-75.82%
144.51
End Cash Position
31.21
-28.22%
43.48
+79.47%
24.23
-30.67%
34.95
Free Cash Flow
-49.17
-9.51%
-44.90
-10.46%
-40.65
-18.38%
-34.34
Interest Paid Supplemental Data
—
—
—
0.00
Amortization Of Securities
-1.67
-1.33%
-1.65
+48.82%
-3.23
-302.75%
-0.80
Common Stock Issuance
138.00
+661.88%
18.11
+479.43%
3.13
-95.90%
76.24
Issuance Of Capital Stock
138.00
+661.88%
18.11
+479.43%
3.13
-95.90%
76.24
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category